Clinical trial shows significant reduction in sudden cardiac death among patients with heart dysfunction — Evidence Review

A new randomized trial suggests that implantable cardioverter-defibrillators (ICDs) may reduce sudden cardiac death in select patients under 70 years of age with mild-to-moderate heart dysfunction and cardiac scarring. Most related studies support the value of ICDs and age-based patient selection, aligning with these findings from the Flinders University study.

• The observed age-dependent benefit of ICDs in the new study is consistent with previous meta-analyses, which highlight greater survival advantages from ICDs in patients younger than 70, suggesting that careful patient selection based on age and risk profile is critical 6.
• Prior research has established that current guidelines restrict ICD use to patients with severe heart dysfunction, yet many sudden deaths occur in those with only mild or moderate impairment, a gap that the present study specifically addresses 1 4.
• Recent studies also indicate that advancements in medical therapy and improved risk stratification have led to a declining overall risk of sudden cardiac death, but the need for improved targeted prevention strategies—such as the use of cardiac MRI to guide ICD implantation—remains 2 5 4.

Study Overview and Key Findings

Sudden cardiac death remains a leading cause of mortality among patients with heart disease, yet most preventive strategies are aimed at those with the most severe reduction in heart function. The recently published randomized controlled trial led by Professor Joseph Selvanayagam expands the evidence base by investigating whether ICDs can benefit patients with mild-to-moderate left ventricular dysfunction and evidence of cardiac scarring—an underserved group in current clinical practice. Unlike prior studies, this trial used cardiac MRI to identify patients at risk, providing a more personalized approach to sudden cardiac death prevention.

Property	Value
Study Year	2026
Organization	Flinders University
Journal Name	Journal of the American Medical Association
Authors	Joseph B. Selvanayagam, John G. F. Cleland, Graham S. Hillis, Sivabaskari Pasupathy, Laurent Billot, Katherine E. George, John J. Atherton, Colin Berry, Ivaylo Tonchev, Chris Gianacas, Werner Jung, Sanjay K. Prasad, Carmine G. De Pasquale, Johannes Brachmann, Anand Ganesan, Rajiv Ananthakrishna, Margaret Arstall, Niall Campbell, Derek T Connelly, David Ferreira, Daniel Garofalo, Jemima Gore, Suchi Grover, John Hill, Nicola Johnston, Alamgir Kabir, David Kaye, Sau Lee, Tina Lin, Scott Lorensini, Jakob Lüker, Paul D MacIntyre, Christian Mahnkopf, Andrew Martin, Gerry P McCann, Ashley Nisbet, Gaetano Nucifora, Bhupesh Pathik, Andreas Pflaumer, Sven Plein, David Prior, Kurt C Roberts-Thomson, Wolfgang Rudolf Bauer, Ranjit Shah, Karthigesh Sree Raman, Martin Stiles, Paul Stobie, Nikola Stoyanov, Rajesh Subbiah, Miriyalini Sundararajah, Sukumaran Thevathasan, Julia Vogler, Tom Wong, Glenn Young, John F Younger, Jufen Zhang, Vlada Zvereva
Population	Patients with mild-to-moderate heart dysfunction and scarring
Sample Size	n=18 sites
Methods	Randomized Controlled Trial (RCT)
Outcome	Sudden cardiac death, serious ventricular arrhythmia
Results	Significant reduction in sudden cardiac death in patients <70 years

Literature Review: Related Studies

To place these findings in context, we searched the Consensus database, which covers over 200 million research papers, for studies relevant to sudden cardiac death, heart failure interventions, and the impact of ICDs and other therapies. The following search queries were used:

1. sudden cardiac death reduction patients
2. cardiac treatment outcomes under 70
3. lifesaving interventions heart disease patients

Below, we summarize key topics and findings from related studies:

Topic	Key Findings
Who benefits most from ICD implantation for sudden cardiac death prevention?	- ICDs provide the greatest survival benefit in patients under 70 with heart failure or cardiomyopathy; benefit decreases with age 6. - Risk stratification tools (e.g., ACC/AHA guidelines, cardiac MRI) help identify high-risk patients who may benefit most from ICDs 1 3.
How have advances in medical therapy affected sudden cardiac death rates?	- The risk of sudden death in heart failure patients has declined over recent decades, attributed to the cumulative effect of evidence-based medical therapies 2 5. - SGLT2 inhibitors further reduce sudden cardiac death risk in heart failure patients on contemporary therapies 5.
What are the current gaps and challenges in preventing sudden cardiac death?	- Many patients who experience sudden cardiac death do not meet current ICD implantation criteria, highlighting a treatment gap 1 4. - Improving risk prediction and broadening patient selection criteria—such as using cardiac MRI to detect scarring—may reduce this gap 1 4.
How does age influence outcomes of cardiac interventions?	- The survival benefit of ICDs in patients with nonischemic systolic heart failure decreases with age, with a marked benefit in those ≤70 years 6. - For other interventions (such as revascularization or transplantation), age should not be the sole criterion, but careful patient selection is essential 7 10.

Who benefits most from ICD implantation for sudden cardiac death prevention?

This topic centers on the identification of patient subgroups who derive the greatest benefit from ICD implantation. The new study's finding that patients under 70 with mild-to-moderate dysfunction and cardiac scarring benefit from ICDs is consistent with prior evidence suggesting age and risk profile are key determinants of ICD efficacy 6. Risk stratification approaches, including use of imaging or guideline-based risk markers, are increasingly important.

• Prior meta-analysis shows that ICDs confer the highest survival benefit in patients ≤70 years, with diminishing returns in older adults 6.
• ACC/AHA and ESC guidelines emphasize individualized risk assessment, which is aligned with the new study's use of cardiac MRI for scarring 1 3.
• Cardiac MRI and enhanced risk algorithms may help identify high-risk patients who fall outside traditional LVEF thresholds 1 3.
• The new study contributes by expanding evidence for ICD benefit to a broader population, guided by imaging and age 6.

How have advances in medical therapy affected sudden cardiac death rates?

The landscape of heart failure management has evolved with the introduction of advanced pharmacotherapies, contributing to a decline in sudden cardiac death rates. The new study builds on this context by assessing whether device therapy provides incremental benefit when modern medical therapy is in place.

• Longitudinal cohort data show a 44% decline in sudden cardiac death among heart failure patients over two decades, attributed to widespread use of evidence-based medications 2.
• SGLT2 inhibitors, a newer class of heart failure therapy, are associated with further reductions in sudden cardiac death risk 5.
• The declining baseline risk may affect the absolute benefit of ICDs, underscoring the need for refined patient selection 2 5.
• The new study addresses whether ICDs provide additional protection beyond current best medical therapy, especially for those with imaging evidence of scarring 5.

What are the current gaps and challenges in preventing sudden cardiac death?

Despite advances, a significant proportion of sudden cardiac deaths occur in patients who do not meet existing criteria for ICD implantation. The present study directly addresses this gap by evaluating ICD efficacy in a population with less severe dysfunction but with cardiac scarring.

• Guidelines currently limit ICDs to patients with severely reduced ejection fraction, leaving many at-risk individuals unprotected 1 4.
• The Lancet Commission highlights the need for better risk prediction tools and broader, more inclusive prevention strategies 4.
• Cardiac MRI for scar detection is a promising approach for expanding the pool of patients who may benefit from ICDs 1 4.
• The new study’s focus on imaging-guided selection is a direct response to these recognized gaps 1 4.

How does age influence outcomes of cardiac interventions?

Age is a critical factor influencing the outcomes of cardiac interventions, including ICDs, revascularization, and transplantation. The new study’s finding of an age cutoff for ICD benefit is consistent with findings in other intervention studies.

• In heart failure, the survival benefit of ICDs declines with age, with a significant threshold at 70 years 6.
• For revascularization and transplantation, age alone should not be a contraindication, but careful selection is required, as older patients may have higher comorbidity burdens or different benefit profiles 7 10.
• The present trial reinforces the need to consider age as part of a nuanced, individualized treatment decision 6 10.
• These findings underscore a movement towards more personalized cardiac care that balances chronological age with biological risk and patient preferences 6 7 10.

Future Research Questions

While the new study advances understanding of ICD use in patients with mild-to-moderate heart dysfunction and scarring, further research is needed to refine risk stratification, optimize selection criteria, and assess long-term outcomes.

Research Question	Relevance
What are the long-term outcomes of ICD implantation in patients with mild-to-moderate heart dysfunction and scarring?	Long-term follow-up is needed to determine durability of benefit, device complications, and quality of life impacts in this expanded patient group, as prior studies have focused on short- to intermediate-term endpoints 6.
How does cardiac MRI scarring quantification improve risk stratification for sudden cardiac death?	Understanding the incremental value of MRI-based scar assessment could refine guidelines and more precisely identify patients who would benefit from ICDs, addressing current gaps in risk prediction 1 4.
What is the optimal age cutoff for ICD implantation benefit?	Previous meta-analyses and the new study suggest age modifies ICD benefit, but further work is needed to define precise thresholds and consider comorbidities for individual decision-making 6 7.
Can biomarkers or genomic profiling improve risk assessment for ICD candidacy?	Integrating molecular risk markers with imaging and clinical features may enhance patient selection for ICDs beyond current criteria 3 4.
How do contemporary medical therapies interact with ICD effectiveness in heart failure?	With declining baseline sudden death risk due to modern therapies, the absolute benefit of ICDs may change; studies are needed to evaluate how new treatments like SGLT2 inhibitors affect ICD outcomes 2 5.

---

This article provides an objective synthesis of the new trial and situates its findings within the broader evidence base, highlighting areas where further research is warranted to optimize care for patients at risk of sudden cardiac death.